CRISPR Therapeutics AG (CRSP) Operating Leases (2019 - 2026)

CRISPR Therapeutics AG (CRSP) has 8 years of Operating Leases data on file, last reported at $183.6 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 9.06% year-over-year to $183.6 million; the trailing twelve-month figure through Mar 2026 stood at $183.6 million (down 9.06% YoY), and the FY2025 full-year result was $188.2 million, down 8.84% from the prior year.
• Operating Leases slipped to $183.6 million in Q1 2026, from $188.2 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $234.2 million in Q2 2022 to a low of $183.6 million in Q1 2026.
• A 5-year average of $214.1 million and a median of $218.9 million in 2024 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases jumped 361.27% in 2022 and declined 9.06% in 2026, its largest moves.
• Tracing CRSP's Operating Leases over 5 years: stood at $228.2 million in 2022, then slipped by 2.27% to $223.0 million in 2023, then slipped by 7.44% to $206.4 million in 2024, then dropped by 8.84% to $188.2 million in 2025, then decreased by 2.45% to $183.6 million in 2026.
• Business Quant data shows CRSP's Operating Leases at $183.6 million in Q1 2026, $188.2 million in Q4 2025, and $192.8 million in Q3 2025.